Sofituzumab vedotin

N/A

Report date: 2024/02/05 14:09:14

Base Information

Drug NameSofituzumab vedotin
Drug Alias NameMMAE anti-MUC16 mAbAnti-MUC16 monoclonal antibody monomethyl auristatin E conjugateAnti-MUC16 ADC MMAEAnti-MUC16 MMAE ADCAnti-MUC16 mAb MMAE +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsMucin-16 stimulants
TargetsMucin-16Tubulin
Therapy Area/IndicationsOvarian NeoplasmsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenentech Inc
Active IndicationsN/A
Inactive IndicationsOvarian NeoplasmsPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia